Livmarli (maralixibat) safely eased severe, treatment-resistant itching in two girls with Alagille syndrome who previously underwent surgical biliary diversion (SBD), a procedure that…
People with hepatitis C who show higher values of liver scarring markers before starting antiviral therapy are significantly more likely to later develop…
The experimental oral therapy linerixibat from GlaxoSmithKline (GSK) offers rapid and sustained relief from severe itch in adults with primary biliary cholangitis (PBC),…
Two new mutations in the USP53 gene were identified as the cause of a milder form of progressive familial intrahepatic cholestasis (PFIC), which resembled…
Excessive intake of sorbitol, a type of sugar naturally found in many fruits and used as a sugar substitute, may increase the risk of metabolic…
Nebokitug, an experimental infusion therapy being developed by Chemomab Therapeutics for primary sclerosing cholangitis (PSC), reduces the inflammatory…
Levels of the metabolite palmitic acid and the protein ACSL1 in the bloodstream can accurately detect the presence and severity of intrahepatic cholestasis of…
Galectin Therapeutics‘ experimental medication belapectin may help reduce liver scarring, or fibrosis, and lower the risk of blood vessel complications in people with metabolic-associated…
Therapy using stem cells derived from donor umbilical cords may help improve outcomes in infants with biliary atresia who have undergone standard Kasai surgery,…
New modeling data predict that bemnifosbuvir and ruzasvir, an experimental combination treatment being developed by Atea Pharmaceuticals for chronic hepatitis C, may…
